BRIDGEWATER, N.J.--(BUSINESS WIRE)--Asana BioSciences, LLC (“Asana,” www.asanabio.com), an independent member of the Amneal Alliance of Companies, has acquired the early stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International plc. Asana is a research and development company specializing in the discovery and development of new chemical and biological entities. The company’s portfolio consists of multiple compounds for oncology and pain indications that are ready to enter clinical trials. Asana is based in Bridgewater, NJ and led by Dr. Sandeep Gupta, Chief Executive Officer, who, until recently, was the Senior Vice President of Discovery and Early Development at Endo Pharmaceuticals.
Dr. Gupta explained, “Asana’s mission is to develop novel and clinically differentiated products that address unmet clinical needs and provide new treatment options to physicians and patients. Our team consists of highly experienced scientists who have successfully executed several drug discovery and clinical development projects. I am very excited about this portfolio and am looking forward to initiating our First-in-Man trials for our lead asset and moving other assets into clinical development.”
“I’m pleased to announce the launch of Asana BioSciences, which expands the Amneal Alliance of Companies’ footprint in pharmaceutical drug discovery, in addition to its generic, specialty and biologics capabilities,” said Chintu Patel, Co-CEO and Co-Chairman of Amneal Pharmaceuticals LLC, a member of the Amneal Alliance of Companies.
About the Amneal Alliance of Companies
The Amneal Alliance of Companies is a powerful alliance of independent companies which focus on various disciplines within the life sciences. Each company is independent of the others but is strategically aligned to bring significant value and growth potential to the alliance members through collaboration and leveraging the strength of the group for the benefit of each member.
Other Alliance members include:
Amneal Pharmaceuticals LLC, headquartered in Bridgewater, New Jersey, develops, manufactures and distributes generic pharmaceutical products and is currently the 7th largest U.S. generics manufacturer in number of prescriptions. It is one of the fastest growing generic pharmaceutical companies and is expanding internationally with global operations in Switzerland, UK, Ireland, India, Spain, Denmark, Germany and Australia. For more information, visit www.amneal.com.
Therapeutic Proteins International, LLC, headquartered in Chicago, Illinois, is a world-class developer of biosimilar recombinant therapeutic proteins. For more information, visit www.theraproteins.com.
Kashiv Pharma, LLC, headquartered in Bridgewater, New Jersey, focuses on innovative delivery technology and provides clients with vital scientific expertise for analyzing and developing difficult or complex dosage forms and drug delivery systems. For more information, visit www.kashivpharma.com.
Prolong Pharmaceuticals, LLC, headquartered in South Plainfield, New Jersey, develops products targeting the treatment of anemia resulting from an oxygen deficiency and is currently focusing on sickle cell disease, chemotherapy, atherosclerosis and diabetes. For more information, visit www.prolongpharma.com.